Online inquiry

IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6474MR)

This product GTTS-WQ6474MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens; Humanized
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6474MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7198MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ564MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 62-71-3
GTTS-WQ4630MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-986016
GTTS-WQ8306MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HM-12525A
GTTS-WQ67MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ5336MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ2184MR IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ALT-803
GTTS-WQ307MR IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 19D12
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW